Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

Longer-term follow-up of nearly four years found that initial treatment with Libtayo was associated with a 14% to 37% further reduction in risk of death. The reported benefit persisted despite 88% of patients initially assigned to placebo crossing over to Libtayo after recurrence.